Sandro Wealth Buys $2.58M HCA Stake as Institutional Ownership Hits 62.73%

For market participants, 13F season is a lagging but valuable map of institutional conviction. Sandro's $2.58M HCA buy is small, but it landed alongside Nomura, Arrowstreet, and Sunbelt adding shares, and HCA opened at $404.61—about 2.8% above its 50-day moving average of $393.41. That combination of persistent flows and technical support makes HCA worth a closer look.

Sandro Wealth Management LLC initiated a new position in HCA Healthcare, Inc. during the second quarter of 2026, purchasing 6,627 shares valued at approximately $2,584,000. According to its latest 13F filing with the SEC, HCA now accounts for about 1.9% of the firm's portfolio and ranks as its 18th largest holding. While Sandro's stake is modest in absolute dollar terms, it sits within a broader wave of institutional accumulation in the hospital operator that includes sharply higher positions from Nomura Asset Management, Advisors Capital Management, Arrowstreet Capital, and Sunbelt Securities. HCA opened at $404.61 on Friday, August 14, 2026, roughly 2.8% above its 50-day simple moving average of $393.41.

“

Sandro's $2.58M HCA buy is small, but it landed alongside Nomura, Arrowstreet, and Sunbelt adding shares, and HCA opened at $404.61—about 2.8% above its 50-day moving average of $393.41.

The cluster of 13F disclosures shows how different categories of institutions are positioning in HCA across quarters. Nomura Asset Management raised its stake by 6.2% in the fourth quarter of 2025, reaching 64,237 shares worth about $29,990,000. Advisors Capital Management was more aggressive, lifting its holdings by 61.5% to 6,836 shares valued at $3,192,000. Arrowstreet Capital, a quantitatively driven manager, increased its already substantial position by 11.9%, adding 245,887 shares to end with 2,311,112 shares worth approximately $1,078,966,000. Sunbelt Securities made the largest percentage move highlighted in the filings, boosting its stake by 171.7% in the first quarter of 2026 to 6,242 shares valued at $2,954,000. Smaller funds were active as well, with names such as Sumitomo Life Insurance, MJP Associates, Cary Street Partners, Anchyra Partners, and Plato Investment Management making incremental purchases.

The significance of these moves extends beyond any single firm's trading decision. HCA is one of the largest for-profit hospital operators in the United States, and healthcare spending has historically provided a defensive profile during periods of economic uncertainty. The fact that institutional investors now own 62.73% of the company's shares means that quarterly 13F flow can be an important supply-demand factor for the stock. When multiple managers with different investment horizons and mandates are adding exposure at the same time, it often reflects a shared view that the company's earnings power, balance sheet, or valuation is attractive. However, 13F filings are backward-looking; they disclose positions as of quarter-end and may not reflect subsequent trades. The filings reviewed here were disclosed on August 16, 2026, covering activity that occurred weeks or months earlier.

From a market microstructure perspective, the stock's technical posture aligns with the accumulation narrative. HCA opened at $404.61 on August 14, above its 50-day simple moving average of $393.41. This suggests that, at least in the short term, the stock has maintained constructive momentum. The implied valuation of Sandro's purchase—about $389.9 per share based on the stated dollar value and share count—is below the August 14 opening price, indicating that the position was likely valued at the June 30 quarter-end price or thereabouts. If HCA shares have risen since quarter-end, the position would now be worth slightly more than the reported $2,584,000.